Studies of Aesculap Implant Systems’ Plasmapore®XP Surface Enhancement indicate that early bone-forming activity was upregulated in osteoblast-like cells that attached to the PlasmaporeXP. In an in vivo sheep model, this yielded an increase in early bone formation, apposition and pullout strength at 12 and 24 weeks.
This is the first published study that provides a direct histological comparison between the PlasmaporeXP surface and uncoated PEEK, and the first peer-reviewed publication to document the presence of nanofeatures created by this proprietary titanium plasma spray manufacturing process.
Study authors believe that the nanofeatures, along with the microporosity and biocompatibility of titanium, may contribute to the significant increase in bone cell differentiation on the PlasmaporeXP surface.
PlasmaporeXP has been warranteed since 2017. In 2018, Aesculap expanded the portfolio with U.S. launch of ArcadiusXP C, a standalone anterior cervical interbody. To date, over 50,000 PlasmaporeXP surface-enhanced interbody devices have been implanted worldwide.
The study, “Porous titanium-coated polyetheretherketone implants exhibit an improved bone–implant interface: an in vitro and in vivo biochemical, biomechanical, and histological study,” is available on the Dove Press website.
Studies of Aesculap Implant Systems' Plasmapore®XP Surface Enhancement indicate that early bone-forming activity was upregulated in osteoblast-like cells that attached to the PlasmaporeXP. In an in vivo sheep model, this yielded an increase in early bone formation, apposition and pullout strength at 12 and 24 weeks.
This is the first...
Studies of Aesculap Implant Systems’ Plasmapore®XP Surface Enhancement indicate that early bone-forming activity was upregulated in osteoblast-like cells that attached to the PlasmaporeXP. In an in vivo sheep model, this yielded an increase in early bone formation, apposition and pullout strength at 12 and 24 weeks.
This is the first published study that provides a direct histological comparison between the PlasmaporeXP surface and uncoated PEEK, and the first peer-reviewed publication to document the presence of nanofeatures created by this proprietary titanium plasma spray manufacturing process.
Study authors believe that the nanofeatures, along with the microporosity and biocompatibility of titanium, may contribute to the significant increase in bone cell differentiation on the PlasmaporeXP surface.
PlasmaporeXP has been warranteed since 2017. In 2018, Aesculap expanded the portfolio with U.S. launch of ArcadiusXP C, a standalone anterior cervical interbody. To date, over 50,000 PlasmaporeXP surface-enhanced interbody devices have been implanted worldwide.
The study, “Porous titanium-coated polyetheretherketone implants exhibit an improved bone–implant interface: an in vitro and in vivo biochemical, biomechanical, and histological study,” is available on the Dove Press website.
Copy to clipboard 
